CN109562145A - 含胰岛素样生长因子-2的药物组合物及其应用 - Google Patents

含胰岛素样生长因子-2的药物组合物及其应用 Download PDF

Info

Publication number
CN109562145A
CN109562145A CN201780048982.3A CN201780048982A CN109562145A CN 109562145 A CN109562145 A CN 109562145A CN 201780048982 A CN201780048982 A CN 201780048982A CN 109562145 A CN109562145 A CN 109562145A
Authority
CN
China
Prior art keywords
macrophage
insulin
growth factor
igf
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780048982.3A
Other languages
English (en)
Other versions
CN109562145B (zh
Inventor
时玉舫
王莹
杜黎明
林良宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institutes for Biological Sciences SIBS of CAS
Original Assignee
Shanghai Institutes for Biological Sciences SIBS of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institutes for Biological Sciences SIBS of CAS filed Critical Shanghai Institutes for Biological Sciences SIBS of CAS
Publication of CN109562145A publication Critical patent/CN109562145A/zh
Application granted granted Critical
Publication of CN109562145B publication Critical patent/CN109562145B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

提供了胰岛素样生长因子‑2在用于制备药物组合物中的用途，该药物组合物用于(i)促进巨噬细胞PD‑L1的表达，和/或(ii)抑制巨噬细胞IL‑1β的表达。还提供了含胰岛素样生长因子‑2作为有效成分的药物组合物。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201780048982.3A 2016-11-29 2017-11-28 含胰岛素样生长因子-2的药物组合物及其应用 Active CN109562145B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611073977.1A CN108114271B (zh) 2016-11-29 2016-11-29 含胰岛素样生长因子-2的药物组合物及其应用
CN2016110739771 2016-11-29
PCT/CN2017/113341 WO2018099363A1 (zh) 2016-11-29 2017-11-28 含胰岛素样生长因子-2的药物组合物及其应用

Publications (2)

Publication Number Publication Date
CN109562145A true CN109562145A (zh) 2019-04-02
CN109562145B CN109562145B (zh) 2023-01-06

Family

ID=62226867

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201611073977.1A Active CN108114271B (zh) 2016-11-29 2016-11-29 含胰岛素样生长因子-2的药物组合物及其应用
CN201780048982.3A Active CN109562145B (zh) 2016-11-29 2017-11-28 含胰岛素样生长因子-2的药物组合物及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201611073977.1A Active CN108114271B (zh) 2016-11-29 2016-11-29 含胰岛素样生长因子-2的药物组合物及其应用

Country Status (5)

Country Link
US (2) US20190381147A1 (zh)
EP (1) EP3549598A4 (zh)
CN (2) CN108114271B (zh)
AU (1) AU2017370226B2 (zh)
WO (1) WO2018099363A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112472798A (zh) * 2020-12-09 2021-03-12 南华大学附属第一医院 胰岛素样生长因子2重组蛋白在制备治疗溃疡性结肠炎药物中的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112546228A (zh) * 2019-09-10 2021-03-26 中国科学院上海营养与健康研究所 非igf1r结合型的物质在预防和/或治疗炎症性疾病中的应用
US20220111011A1 (en) * 2020-10-13 2022-04-14 Betavive Ltd. Method and Compounds for Treating Diabetes and Associated Metabolic Diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025227A1 (en) * 1992-06-08 1993-12-23 Kabi Pharmacia Ab Use of growth factor igf-ii
CN1469752A (zh) * 2000-08-29 2004-01-21 通过给予igf结构类似物治疗中枢神经系统疾病的方法
CN105007942A (zh) * 2013-03-07 2015-10-28 勃林格殷格翰国际有限公司 用于瘤形成治疗的组合疗法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002246619A1 (en) * 2000-12-08 2003-06-23 Neuronz Limited Use of insuline-like growth factor-i for promoting remyelination of axons
US20040138116A1 (en) * 2002-08-30 2004-07-15 Vincent Geenen Tolerogenic approach for type 1 diabetes
CN101466398A (zh) * 2006-06-09 2009-06-24 诺瓦提斯公司 稳定的胰岛素样生长因子多肽
CN102830223A (zh) * 2012-08-14 2012-12-19 四川汇宇制药有限公司 一种筛选治疗哺乳动物肿瘤疾病药物的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025227A1 (en) * 1992-06-08 1993-12-23 Kabi Pharmacia Ab Use of growth factor igf-ii
CN1469752A (zh) * 2000-08-29 2004-01-21 通过给予igf结构类似物治疗中枢神经系统疾病的方法
CN105007942A (zh) * 2013-03-07 2015-10-28 勃林格殷格翰国际有限公司 用于瘤形成治疗的组合疗法

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ERIN C. STEINBACH等: "The Role of Macrophages and Dendritic Cells in the Initiation of Inflammation in IBD", 《INFLAMMATORY BOWEL DISEASES》 *
GUI YANG等: "Insulin-like growth factor 2 enhances regulatory T-cell functions and suppresses food allergy in an experimental model", 《JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY》 *
J.CHEN等: "Regulation of PD-L1: a novel role of pro-survival signalling in cancer", 《ANNALS OF ONCOLOGY》 *
KAZUNORI HAMAMURA等: "IGF2-driven PI3 kinase and TGFb signaling pathways in chondrogenesis", 《CELL BIOLOGY INTERNATIONAL》 *
NORIAKI KAWANISHI等: "Macrophage depletion by clodronate liposome attenuates muscle injury and inflammation following exhaustive exercise", 《BIOCHEMISTRY AND BIOPHYSICS REPORTS》 *
TOMOYA UCHIMURA等: "Insulin-Like Growth Factor II (IGF-II) Inhibits IL-1b-Induced Cartilage Matrix Loss and Promotes Cartilage Integrity in Experimental Osteoarthritis", 《JOURNAL OF CELLULAR BIOCHEMISTRY》 *
尚晓峰: "调节性T细胞在实验性变态反应性脑脊髓炎和多发性硬化发病中的作用", 《中华神经医学杂志》 *
杨丽娟等: "Thl7细胞与Thl、Treg细胞关系的研究进展", 《免疫学杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112472798A (zh) * 2020-12-09 2021-03-12 南华大学附属第一医院 胰岛素样生长因子2重组蛋白在制备治疗溃疡性结肠炎药物中的应用

Also Published As

Publication number Publication date
EP3549598A1 (en) 2019-10-09
AU2017370226B2 (en) 2021-05-20
AU2017370226A1 (en) 2019-08-01
EP3549598A4 (en) 2020-06-03
WO2018099363A1 (zh) 2018-06-07
CN108114271A (zh) 2018-06-05
CN108114271B (zh) 2021-07-02
CN109562145B (zh) 2023-01-06
US20190381147A1 (en) 2019-12-19
US20230364201A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
Lee et al. Chronic tissue inflammation and metabolic disease
Bai et al. Novel anti-inflammatory action of 5-aminoimidazole-4-carboxamide ribonucleoside with protective effect in dextran sulfate sodium-induced acute and chronic colitis
Spiller et al. Macrophage-based therapeutic strategies in regenerative medicine
Xiang et al. Kinsenoside attenuates liver fibro-inflammation by suppressing dendritic cells via the PI3K-AKT-FoxO1 pathway
Tencerova et al. Activated Kupffer cells inhibit insulin sensitivity in obese mice
US20230364201A1 (en) Pharmaceutical composition containing insulin-like growth factor-2 and use thereof
WO2021050093A1 (en) A method of reducing viability of cancer cells by applying alternating electric fields and administering checkpoint inhibitors to the cancer cells
EP2992881A1 (en) Pharmaceutical composition for inhibiting immune response through inducing differentiation into regulator t cells and promoting proliferation of regulator t cells
CN108486196A (zh) 一种淫羊藿次苷i或淫羊藿次苷c的制备方法
WO2016184427A1 (zh) 低氧处理的间充质干细胞及其应用
EP3088526A1 (en) Use of mirna-214 inhibitor in inhibiting regulatory t cells
EP3023104B1 (en) Recombinant ganoderma lucidum immunomodulatory protein (rlz-8) for use in treating melanoma
CN109844101A (zh) 使用极化巨噬细胞的细胞疗法，用于组织再生
Cumberbatch et al. Inhibition by dexamethasone of Langerhans cell migration: influence of epidermal cytokine signals
Bradley et al. Adipose tissue T regulatory cells: implications for health and disease
Stutte et al. Type I interferon mediated induction of somatostatin leads to suppression of ghrelin and appetite thereby promoting viral immunity in mice
CN106687583A (zh) 用于制备具有增加的特异性基因表达的树突细胞的方法和包含使用所述方法制备的树突细胞的用于治疗或预防自身免疫性疾病的组合物
BEVER JR et al. A comparison of interferon responses to poly ICLC in males and females
Tyndel Hyaluronidase as an adjuvant in insulin shock therapy
Yamamoto et al. Plasma lipid-lowering and lipogenesis-stimulating actions of ginseng saponins in tumor-bearing rats
CN109432116A (zh) 黄芪皂苷ⅲ在制备肿瘤免疫治疗药物中的用途
Xiu et al. Sauchinone attenuates inflammatory responses in dendritic cells via Blimp-1 and ameliorates dextran sulfate sodium (DSS)-induced colitis
CN100572530C (zh) 使用L-α-溶血磷脂酰胆碱获得单核细胞体外分化成成熟树突细胞
AU2008265973A1 (en) Methods of restoration of erectile function
US9833473B2 (en) Tolerogenic dendritic cells for treating myocardial infarction and manufacturing method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 200031 Yueyang Road, Shanghai, No. 319, No.

Applicant after: Shanghai Institute of nutrition and health, Chinese Academy of Sciences

Address before: 200031 Yueyang Road, Shanghai, No. 319, No.

Applicant before: SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant